RxDoctor Payments Data

Tetyana Falkenberry, MD

Family Medicine · Mobile, ALNPI 1710152582

Payments from drug & device makers

$707in general payments, 2019–2025

Across 24 payments — averaging $29.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$168
  • Eyevance Pharmaceuticals LLC$160
  • GSK$94
  • Gilead$79
  • ANI Pharmaceuticals, Inc.$60
  • AbbVie$33
  • plus $112 from 7 others

What the payments were for

  • Food & beverage$707100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$168
Eyevance Pharmaceuticals LLC1$160
GSK5$94
Gilead4$79
ANI Pharmaceuticals, Inc.2$60
AbbVie2$33
Shield Therapeutics Inc1$23
Amgen1$18
Cipher Pharmaceuticals US LLC1$18
Medtronic1$15
Dexcom, Inc.1$13
Merck1$13
Novo Nordisk1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$707 in reported general payments places this provider in the 50th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$2,351
Medicare patients
13
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$85,817
JardianceEmpagliflozin29$40,234
MounjaroTirzepatide24$34,771
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$26,786
FarxigaDapagliflozin Propanediol21$20,320
LinzessLinaclotide19$19,159
JanuviaSitagliptin Phosphate15$18,252
EliquisApixaban12$14,192
Breo ElliptaFluticasone/Vilanterol12$7,347
VascepaIcosapent Ethyl18$7,334
SymbicortBudesonide/Formoterol Fumarate18$7,146
Advair HfaFluticasone Propion/Salmeterol11$4,318
Varenicline Tartrate20$3,109
Albuterol Sulfate HfaAlbuterol Sulfate124$2,935
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$12$85,81764 claims
GSKTrelegy Ellipta, Breo Ellipta$94$34,13333 claims
AstraZenecaFarxiga, Symbicort$168$27,46539 claims
AbbVieLinzess$33$19,15919 claims
MerckJanuvia$13$18,25215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →